…
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Alzamend Neuro Inc is a clinical-stage biopharmaceutical company developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. Its long-term growth may benefit from aging demographics, large unmet needs for disease-modifying treatments, and potential clinical or regulatory milestones that could validate its programs and advance commercialization prospects.
The company faces material risks from inherent clinical and regulatory uncertainty, likely need for continued capital, and intense competition in the neuroscience drug development sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 |
| Income before tax | -4.51M | -9.95M | -14.88M | -12.36M | -5.05M |
| Net income | -4.51M | -9.95M | -14.88M | -12.40M | -5.20M |
| Selling general administrative | 3.08M | 3.48M | 6.68M | 7.12M | 3.64M |
| Selling and marketing expenses | - | 0.25M | 0.74M | - | - |
| Gross profit | -0.05M | -0.05M | - | - | - |
| Reconciled depreciation | 0.05M | 0.05M | 0.02M | 0.00M | - |
| Ebit | -4.50M | -9.94M | -14.87M | -12.32M | -4.95M |
| Ebitda | -4.45M | -9.89M | -14.85M | -12.32M | -4.95M |
| Depreciation and amortization | 0.05M | 0.05M | 0.02M | 0.00M | 0.00M |
| Non operating income net other | - | - | - | 0.00M | 0.06M |
| Operating income | -4.50M | -9.94M | -14.87M | -12.32M | -4.95M |
| Other operating expenses | 4.50M | 9.94M | 14.87M | 12.32M | 4.95M |
| Interest expense | 0.02M | 0.01M | 0.01M | 0.05M | 0.16M |
| Interest income | - | - | - | 0.00M | 0.00M |
| Net interest income | -0.02M | -0.01M | -0.01M | -0.05M | -0.16M |
| Income tax expense | - | - | - | 0.04M | 0.16M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 4.45M | 9.94M | 14.87M | 12.32M | 4.95M |
| Cost of revenue | 0.05M | 0.05M | - | - | - |
| Total other income expense net | -0.02M | -0.01M | -0.01M | -0.04M | -0.09M |
| Net income from continuing ops | -4.51M | -9.95M | -14.88M | -12.36M | -5.05M |
| Net income applicable to common shares | - | - | -14.88M | -12.36M | -5.05M |
| Breakdown | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 |
| Total assets | 4.60M | 0.63M | 5.92M | 14.52M | 2.91M |
| Other current assets | 0.23M | 0.08M | 0.69M | 0.35M | 0.98M |
| Total liab | 0.63M | 3.23M | 2.87M | 1.16M | 0.90M |
| Total stockholder equity | 3.97M | -2.59M | 3.05M | 13.35M | 2.01M |
| Other current liab | - | 3.23M | 2.87M | 0.00M | 0.06M |
| Common stock | 0.00M | 0.00M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.00M | 0.00M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -58.54M | -54.02M | -44.07M | -29.19M | -16.83M |
| Cash | 3.95M | 0.38M | 5.14M | 14.06M | 1.93M |
| Total current liabilities | 0.63M | 3.23M | 2.87M | 1.16M | 0.90M |
| Current deferred revenue | - | -3.23M | - | - | - |
| Net debt | -3.95M | -0.08M | -5.14M | -14.06M | -1.59M |
| Short term debt | - | 0.30M | - | - | 0.34M |
| Short long term debt | - | 0.30M | - | - | 0.34M |
| Short long term debt total | - | 0.30M | - | - | 0.34M |
| Other stockholder equity | 62.50M | 51.43M | 47.11M | 42.54M | 18.84M |
| Property plant equipment | - | - | 0.08M | 0.10M | - |
| Total current assets | 4.18M | 0.46M | 5.84M | 14.41M | 2.91M |
| Net tangible assets | - | - | 3.05M | 13.35M | 2.01M |
| Net receivables | - | - | - | - | 0.02M |
| Inventory | - | - | - | - | -0.02M |
| Accounts payable | 0.63M | 2.93M | 2.87M | 1.16M | 0.50M |
| Accumulated other comprehensive income | - | 0.00M | - | - | - |
| Common stock total equity | - | - | 0.01M | 0.01M | 0.01M |
| Preferred stock total equity | - | - | - | - | 0.00M |
| Retained earnings total equity | - | - | -44.07M | -29.19M | -16.83M |
| Non current assets total | 0.43M | 0.18M | 0.08M | 0.10M | 0.00M |
| Breakdown | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 |
| Investments | -0.30M | -0.15M | 0.00M | -0.11M | 0.10M |
| Change to liabilities | - | - | 1.71M | 0.69M | -0.41M |
| Total cashflows from investing activities | -0.30M | -0.15M | - | -0.11M | 0.10M |
| Net borrowings | 0.00M | 0.30M | - | -0.06M | 2.25M |
| Total cash from financing activities | 10.44M | 3.65M | 0.00M | 18.85M | 4.45M |
| Change to operating activities | - | - | 0.64M | 0.63M | 0.26M |
| Net income | -4.51M | -9.95M | -14.88M | -12.36M | -5.05M |
| Change in cash | 3.57M | -4.76M | -8.92M | 12.13M | 1.84M |
| Begin period cash flow | 0.38M | 5.14M | 14.06M | 1.93M | 0.09M |
| End period cash flow | 3.95M | 0.38M | 5.14M | 14.06M | 1.93M |
| Total cash from operating activities | -6.57M | -8.27M | -8.92M | -6.61M | -2.71M |
| Issuance of capital stock | 10.44M | 3.35M | 0.00M | 18.91M | 2.10M |
| Depreciation | 0.05M | 0.05M | 0.02M | 0.00M | 0.12M |
| Other cashflows from investing activities | - | - | - | -0.11M | 0.10M |
| Sale purchase of stock | - | - | 0.00M | 6.00M | 2.10M |
| Other cashflows from financing activities | 7.74M | 2.10M | -0.99M | 0.00M | 2.35M |
| Change to netincome | - | - | 3.58M | 4.40M | 2.49M |
| Capital expenditures | 0.30M | 0.15M | 0.00M | 0.11M | 0.11M |
| Cash flows other operating | - | - | 0.64M | 0.63M | 0.65M |
| Cash and cash equivalents changes | - | - | -8.92M | 12.13M | 1.84M |
| Change in working capital | -2.44M | 0.67M | 2.35M | 1.33M | -0.15M |
| Stock based compensation | 0.33M | 0.96M | 3.58M | 4.41M | 2.03M |
| Other non cash items | 0.01M | 0.00M | 1.71M | 0.01M | 0.45M |
| Free cash flow | -6.87M | -8.42M | -8.92M | -6.72M | -2.71M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ALZN Alzamend Neuro Inc |
0.02 1.80% |
1.13 | - | - | - | 1.93 | -3.13 |
| NVO Novo Nordisk A/S |
-0.99 2.39% |
40.60 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.90 0.73% |
533.89 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.36 0.56% |
957.76 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephan Jackman | CEO & Director | 1976 |
| Mr. Kenneth S. Cragun CPA | Sr. VP of Fin. | 1961 |
| Mr. David J. Katzoff | Chief Financial Officer | 1962 |
| Mr. Henry C. W. Nisser Esq. | Exec. VP, Gen. Counsel & Director | 1969 |
| Mr. Stephan Jackman | CEO & Director | 1977 |
| Mr. David J. Katzoff | Chief Financial Officer | 1963 |
| Mr. Milton Charles Ault III | Founder & Vice Chairman | 1970 |
| Mr. Henry C. W. Nisser Esq. | Executive VP, General Counsel & Director | 1970 |
| Mr. Kenneth S. Cragun CPA | Senior Vice President of Finance | 1961 |
| Mr. Henry C. W. Nisser Esq. | Executive VP, General Counsel & Director | 1969 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.